ClinicalTrials.gg
RecruitingNCT07473947Updated Jun 3, 2026

Performance and Safety Follow-up of Bioabsorbable Headless Inion CompressOnTM Screws in the Fixation of Bone Fractures in Ankle, Knee and Elbow of Pediatric and Adolescent Patients

An interventional study of Fracture fixation operation in Ankle Fractures, Knee Fractures and Elbow Fractures, sponsored by Inion Oy. Recruiting at 1 site in Finland. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Inion Oy · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
Up to 17 Years
Sex
All
01

Study summary

The study in question is a post market clinical follow up (PMCF) study to follow up the safety and performance of bioabsorbable headless compression screw Inion CompressOn in fracture fixation of the ankle, knee and elbow of pediatric and adolescent patients. The study aims to recruit 80 patients who meet the acceptance criteria. The follow-up time for each study patient is 4 years. The study is a single center single group study which is conducted in Lighthouse Hospital at Turku University Hospital (TYKS) in Finland. The main focus of the study in terms of performance is to follow up the bone healing/ossification of operated areas. The main focus of the study in terms of safety is to evaluate the occurrence of adverse events and required revision surgeries that are or might be related to the study device.

Read the detailed description

The study in question is a post market clinical follow-up study to follow-up the safety and performance of the bioabsorbable headless Inion CompressOn Screw in fracture fixation operations of the ankle, knee and elbow of pediatric and adolescent patients. The main focus of the study in terms of performance is to follow-up the bone healing/ossification of operated areas. The main focus of the study in terms of safety is to evaluate the occurrence of adverse events and required revision surgeries that are or might be related to the study device.

The Inion CompressOn™ Screws are cannulated headless compression screws made of degradable co-polymers composed of L-lactic acid and D-lactic acid. These polymers have a long history of safe medical use and they degrade in vivo by hydrolysis into alpha-hydroxyacids that are metabolised by the body. The screws retain their initial strength up to 12 weeks after implantation and gradually lose their strength thereafter. Bioabsorption takes place within four years.

The clinical data collection acquired from this study is a requirement of the EU Notified Body as part of the admitted CE mark certification, in cases when the device is initially approved based on the clinical data of an equivalent device. In this case, the equivalent device has been Inion FreedomScrew, which is made of the same material composition and is used for the same indications. Inion CompressOn Screw has new design features such as headless design, and threading which allows compression to the fracture line. Also new sizes have been introduced.

The study recruits 80 pediatric/adolescent patients who meet the acceptance criteria and have signed the informed consent. The follow-up time for each study patient is 4 years. Each patient has 6 follow-up time points related to the study. These time points consist of:

  1. screening visit (-180-0 days before operation),
  2. operation (day 0),
  3. post-operative follow-up 1 (4-8 weeks),
  4. post-operative follow-up 2 (3 months after operation +/- 3 weeks),
  5. post-operative follow-up 3 (2 years after operation +/- 2 months)
  6. post-operative follow-up 4 (4 years after operation +/- 4 months) The first 4 time points are within standard care, the last 2 time points (post-operative follow-up 3 and post-operative follow-up 4) are scheduled for study purposes only to be able to gain performance and safety data based on adequate follow-up time.

The study is a single center single group study which is conducted in Turku University Hospital (TYKS) in Finland.

02

Conditions studied

  • Ankle Fractures
  • Knee Fractures
  • Elbow Fractures

Keywords

  • bioabsorbable
  • resorbable
  • ankle fracture
  • knee fracture
  • elbow fracture
  • fracture fixation
03

In context

Ankle Fractures

203 studies on the registry are indexed under Ankle Fractures; 45 are open to participants now.

This study's planned enrollment of 80 is below the median of 90 across 151 interventional studies indexed under Ankle Fractures.

Browse Ankle Fractures studies →

Lead sponsor

Inion Oy is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. signed by parents or legal guardians, and assent from the child if of appropriate age and cognitive ability \< 18 years 3. Suitable and in need for an operation indicated for subject device 4. Ability to give adequate input for the PROM questionnaires 5. Willingness and ability to comply with rehabilitation instructions. 6. Availability for follow-up visits.

Exclusion criteria

Exclusion Criteria:

  1. Active infection
  2. Patient conditions including limited blood supply (e.g. patients with severe circulatory disorder of the lower or upper limb)
  3. Patient conditions including insufficient quality or quantity of bone (diagnosed osteoporosis, conditions causing secondary osteoporosis e.g. diabetes, rheumatism, eating disorder)
  4. Patient conditions where patient cooperation cannot be guaranteed (alcohol use, drug abuse etc.)
  5. Patients with known allergy to the implant constituents or its degradation products.
  6. Spinal and craniomaxillofacial indications.
  7. High-load bearing indications (e.g., diaphyseal fractures of long bones) unless used in conjunction with traditional rigid fixation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    CompressOn group

    Participants undergo a surgical fracture fixation procedure using the bioabsorbable Inion CompressOn Screw according to the device instructions for use.

    Device: Fracture fixation operation

Interventions

  • DeviceFracture fixation operation

    Fracture fixation operation in using bioabsorbable headless Inion CompressOn Screw/s according to instructions for use

06

What researchers measure

Primary outcomes

  1. Bone healing (ossification) of the fracture line(s)

    X-ray evaluation of bone healing (ossification) of the fracture line(s)

    Time frame: Change from operation to 4 years

  2. Occurrence of device-related adverse events

    Assessment of occurrence of adverse events (AE), that are or might be related to the study device such as non-union of bone, fixation failure, mechanical irritation and tissue reactions related to implant bioabsorption

    Time frame: During 4-year follow-up

  3. Occurrence of revision surgeries

    Assessment of occurrence of revision surgeries related to study device

    Time frame: During 4-year follow-up

Secondary outcomes

  1. Subjective functionality of the operated limb (Visual Analogue Scale, VAS)

    Evaluation of subjective pain of the operated area during follow-up. 10-cm (100-mm) horizontal line used to measure pain intensity, ranging from "no pain" (0) to "worst imaginable pain" (100 mm)

    Time frame: Change from baseline to 4 years

  2. Subjective functionality of the operated area (Lower Extremity Functional Scale, LEFS/Upper Extremity Functional Index, UEFI)

    Evaluation of subjective functionality of the operated area follow-up. UEFI: The scores given to the 20 questions are added to give a highest possible score of 80. The lowest possible score is 0. A lower score indicates that the person is reporting increased difficulty with the activities as a result of their upper limb condition. LEFS: Contains 20 questions about a person's ability to perform everyday tasks. The maximum score is 80. The lower the score the greater the disability.

    Time frame: Change from baseline to 4 years

07

Study locations

1 of 1 sites recruiting
  • Turku University Hospital/Lighthouse hospital
    Turku, 20520, Finland
    Recruiting
    • Olli Pajulo, MD · Contactolli.pajulo@varha.fi · +358 2 313 0000
    • Olli Pajulo, MD · Principal investigator
    • Johanna Syvänen, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Feb 2032, 69 months after the start.

Of 72 interventional studies with no phase under Ankle Fractures, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 69 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 16, 2026
StartActual
May 29, 2026
Primary completionEst.
Feb 2032
CompletionEst.
Dec 2032
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07473947
Lead sponsor
Inion Oy
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
May 29, 2026
Primary completion
Feb 2032 (estimated)
Completion
Dec 2032 (estimated)
Last update
Jun 3, 2026

Study contacts

Marika Manni, MD
Contact
marika.manni@inion.com
+358503669994
Kati Marttinen
Contact
kati.marttinen@inion.com
+358 40 841 6217
Olli Pajulo, MD
principal investigator · Turku University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion